Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 2 de 2
Filtrar
Más filtros




Base de datos
Intervalo de año de publicación
1.
Eur J Med Chem ; 277: 116730, 2024 Nov 05.
Artículo en Inglés | MEDLINE | ID: mdl-39111015

RESUMEN

In this paper we report the discovery of structurally novel and highly potent programmed cell death-ligand 1 (PD-L1) inhibitors targeting surface and intracellular PD-L1. A ring fusion design utilizing dimethoxyphenyl indazole derivatives was used, followed by structural extension, which further improved potency by inducing the formation of additional symmetrical interactions within the PD-L1 binding site, leading to the discovery of novel and highly active tetra-aryl-scaffold inhibitors. Key optimizations involved polar tail chain modifications that improve potency and minimize cell cytotoxicity. In addition, druggability issues that exist outside the rule-of-five chemical space were addressed. CB31, a representative compound, was found to exhibit outstanding activity in blocking programmed cell death-1 (PD-1)/PD-L1 interactions (IC50 = 0.2 nM) and enhancing T-cell functions, with minimal cell cytotoxicity. CB31 also displayed favorable oral pharmacokinetic properties, consistent with its high passive permeability and insusceptibility to efflux transporters, as well as its high metabolic stability. Additionally, CB31 demonstrated mechanistically differentiated features from monoclonal antibodies by inducing PD-L1 internalization, intracellular retention of PD-L1 with altered glycosylation pattern, and PD-L1 degradation. It also demonstrated greater effects on tumor size reduction and tumor cell killing, with enhanced T-cell infiltration, in a 3D tumor spheroid model. Overall, results show that CB31 is a promising small-molecule PD-L1 inhibitor that can inhibit PD-1/PD-L1 interactions and promote PD-L1 degradation.


Asunto(s)
Antígeno B7-H1 , Diseño de Fármacos , Humanos , Antígeno B7-H1/antagonistas & inhibidores , Antígeno B7-H1/metabolismo , Relación Estructura-Actividad , Animales , Estructura Molecular , Administración Oral , Ratones , Relación Dosis-Respuesta a Droga , Antineoplásicos/farmacología , Antineoplásicos/química , Antineoplásicos/síntesis química , Inhibidores de Puntos de Control Inmunológico/farmacología , Inhibidores de Puntos de Control Inmunológico/síntesis química , Inhibidores de Puntos de Control Inmunológico/química , Ensayos de Selección de Medicamentos Antitumorales , Disponibilidad Biológica , Proliferación Celular/efectos de los fármacos , Línea Celular Tumoral
2.
Org Biomol Chem ; 14(46): 11002-11012, 2016 Nov 22.
Artículo en Inglés | MEDLINE | ID: mdl-27827507

RESUMEN

F-THENA is designed as an alternative fluorine-containing chiral derivatizing agent (CDA). The fluorine atom functions exclusively as a reporter which can directly sense an anisotropic effect from an aromatic substituent of a chiral alcohol. In combination with chemical shift differences from both 19F NMR and 1H NMR, the F-THENA method can successfully be used for determining the absolute configuration of chiral secondary aromatic alcohols with a self-validating system.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA